Ozempic vs. Mounjaro: Which Is Better? Side-by-Side Comparison

Which is better, Ozempic or Mounjaro? If your main goal is to lower blood sugar and lose weight while managing type 2 diabetes, Mounjaro may be the better choice. Clinical studies have shown that Mounjaro can produce greater reductions in blood sugar and body weight than Ozempic at the doses studied.

But Ozempic has advantages of its own. For example, if you have type 2 diabetes and chronic kidney disease, Ozempic may be a better option because it is FDA-approved to reduce the risk of certain serious kidney complications. Both medications also offer cardiovascular benefits for eligible patients.

So, which one should you choose? It depends on what you’re trying to accomplish and your medical history. Ozempic contains semaglutide, while Mounjaro contains tirzepatide, and they work differently in the body. Both can help manage type 2 diabetes and support weight loss, but neither is FDA-approved specifically for weight management.

Ultimately, the best choice is the medication that addresses your health priorities while being safe and appropriate for your individual needs.

DFWPMA offers GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications to eligible patients when medically appropriate, subject to medication availability.

DFWPMA offers in-person GLP-1 prescription evaluations in Texas and can prescribe GLP-1 medications at a DFWPMA location across Texas to eligible patients when medically appropriate, subject to medication availability.

Our primary care providers and endocrinologists also offer ongoing care to monitor potential side effects, address health concerns, and support patients throughout GLP-1 treatment. DFWPMA does not currently offer online GLP-1 prescriptions, an in-person evaluation is required.

Book an appointment online or call (903) 957-0082 to contact our scheduling team.

Get Prescriptions for GLP-1 Medications at a DFWPMA Location Near You!

📍 GLP-1 Prescription Providers in Fort Worth, TX

1220 W Presidio St, Fort Worth, TX 76102

Book an Appointment at Our Fort Worth Location →
📍 GLP-1 Prescription Providers in Frisco, TX

7589 Preston Rd., Suite 900, Frisco, TX 75034

Book an Appointment at Our Frisco Location →
📍 GLP-1 Prescription Providers in Sherman, TX

425 N Highland Ave., Suite 260, Sherman, TX 75092

Book an Appointment at Our Sherman Location →
📞 Call DFWPMA to Schedule

Speak with our scheduling team about GLP-1 prescription evaluations, provider availability, and appointments.

Call Us → (903) 957-0082

We accept many major insurance plans. Not sure if your plan is accepted?

Call (903) 957-0082 and our team can help verify coverage.

What Is Ozempic?

Ozempic (semaglutide) is a prescription GLP-1 receptor agonist primarily used to improve blood sugar control in adults with type 2 diabetes. It also reduces the risk of major cardiovascular events in eligible adults with type 2 diabetes and certain kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease.

Ozempic works by stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and slowing gastric emptying. It can also reduce appetite and promote weight loss, although Ozempic is not FDA-approved specifically for weight management.

ozempic

What Is Mounjaro?

Mounjaro (tirzepatide) is a prescription dual GIP and GLP-1 receptor agonist approved to improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes. It is also approved to reduce major cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk.

Mounjaro activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action improves glucose-dependent insulin secretion, reduces glucagon levels, and helps regulate appetite and food intake. Mounjaro can also produce substantial weight loss, although it is not FDA-approved specifically for chronic weight management.

Ozempic vs. Mounjaro: Side by Side Comparison

Ozempic and Mounjaro differ primarily in their active ingredients, mechanisms of action, blood sugar-lowering effectiveness, and weight-loss potential. Both are FDA-approved for type 2 diabetes management and certain cardiovascular risk-reduction indications. Mounjaro has demonstrated greater average HbA1c and weight reductions than Ozempic 1 mg in a direct clinical trial, while Ozempic has an additional approved indication for certain patients with diabetic chronic kidney disease.

ComparisonOzempicMounjaro
ManufacturerNovo NordiskEli Lilly and Company
Pricing

Manufacturer self-pay offers:

  • Introductory Offer: Starting at $199/month for eligible new injection patients during a limited promotional period.
  • Standard Injection Offers: Approximately $349–$499/month, depending on dose and eligibility.
  • Oral Formulation: Self-pay offers starting at $149/month.

Retail prices may be higher.

Manufacturer pricing and savings:

  • Self-Pay Options: Starting at $499/month through eligible LillyDirect purchasing options.
  • Manufacturer List Price: Approximately $1,112 for a 28-day supply before discounts or insurance.
  • Savings Eligibility: Discounts depend on insurance status, approved use, and program requirements.

Actual pharmacy prices may vary.

Insurance Coverage
  • Commercial Insurance: Many plans cover Ozempic for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available for medically eligible beneficiaries.
  • Weight Loss Alone: Generally not covered because Ozempic is not approved specifically for weight management.
  • Commercial Insurance: Many plans cover Mounjaro for eligible patients with type 2 diabetes.
  • Medicare Part D: Coverage may be available for eligible beneficiaries with qualifying medical indications.
  • Prior Authorization: Insurers may require a type 2 diabetes diagnosis and supporting medical documentation.
  • Weight Loss Alone: Generally not covered because Mounjaro is not approved specifically for weight management.
Main PurposeImprove blood sugar control in adults with type 2 diabetes.Improve blood sugar control in adults and children aged 10 years and older with type 2 diabetes.
Secondary Purposes
  • Cardiovascular Protection: Reduce major cardiovascular events in eligible adults with type 2 diabetes.
  • Kidney Protection: Reduce certain kidney and cardiovascular risks in adults with type 2 diabetes and chronic kidney disease.
  • Cardiovascular Protection: Reduce major cardiovascular events in adults with type 2 diabetes who are at high cardiovascular risk.
  • Weight Reduction: May produce substantial weight loss as an additional treatment effect, although weight management is not an approved Mounjaro indication.
Active IngredientSemaglutide, a GLP-1 receptor agonist.Tirzepatide, a dual GIP and GLP-1 receptor agonist.
Benefits
  • Blood Sugar Control: Lowers blood glucose and HbA1c.
  • Weight Management: May promote weight loss.
  • Cardiovascular Health: Reduces certain cardiovascular risks in eligible adults with type 2 diabetes.
  • Kidney Health: Provides demonstrated benefits in specified patients with diabetic chronic kidney disease.
  • Blood Sugar Control: Produces substantial reductions in blood glucose and HbA1c.
  • Weight Loss: Can produce clinically meaningful weight reduction in patients with type 2 diabetes.
  • Appetite Regulation: Helps reduce hunger and food intake.
  • Cardiovascular Health: Reduces major cardiovascular events in eligible adults with type 2 diabetes at high cardiovascular risk.
Potential Health Risks
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Possible worsening of diabetic retinopathy.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
  • Pancreatitis: Potential acute pancreatic inflammation.
  • Gallbladder Problems: Including gallstones and gallbladder inflammation.
  • Kidney Injury: Possible dehydration-related acute kidney injury.
  • Eye Complications: Diabetic retinopathy requires appropriate monitoring.
  • Thyroid Warning: Boxed warning for thyroid C-cell tumors observed in rodents.
Weight Loss PotentialCan produce clinically meaningful weight loss in adults with type 2 diabetes, depending on dose, patient characteristics, and treatment duration. Ozempic is not approved specifically for weight loss.In the SURPASS-2 trial involving adults with type 2 diabetes, Mounjaro produced approximately 7.6–11.2 kg (17–25 lb) of average weight loss over 40 weeks, depending on dose, compared with approximately 5.7 kg (13 lb) for semaglutide 1 mg. Mounjaro is not approved specifically for weight loss.
Administration
  • Injection: Subcutaneous injection once weekly.
  • Oral Tablet: Once-daily oral formulation with specific administration instructions.
  • Injection: Subcutaneous injection once weekly.
  • Injection Sites: Abdomen, thigh, or upper arm.
  • Available Forms: Prefilled injection pens, including available multidose pen presentations.
Dosing Considerations
  • Starting Injection Dose: Typically 0.25 mg weekly.
  • Dose Escalation: Gradual increases based on treatment response and tolerability.
  • Oral Dosing: Follows a separate daily dosing schedule.
  • Starting Dose: Typically 2.5 mg weekly.
  • Dose Escalation: Gradual increases in 2.5 mg increments according to the prescribing schedule and tolerability.
  • Maximum Adult Dose: 15 mg once weekly.
Who May Benefit Most?Adults with type 2 diabetes, particularly those who also meet the criteria for its cardiovascular or kidney risk-reduction indications.Patients aged 10 years and older with type 2 diabetes who need improved blood sugar control, including adults who may benefit from greater HbA1c reduction or additional weight loss. Adults at high cardiovascular risk may also benefit from its approved cardiovascular indication.
How Fast Does It Work?
  • Blood Sugar: Improvements may begin within the first weeks.
  • HbA1c: Reductions are generally assessed over approximately 3 months.
  • Weight Loss: Typically develops gradually over several months.
  • Blood Sugar: Improvements may begin within the first weeks of treatment.
  • HbA1c: Meaningful reductions generally develop over several weeks to months, with major trials assessing outcomes at 40–52 weeks.
  • Weight Loss: May begin within several weeks and continue over subsequent months.
Potential Side Effects
  • Digestive: Nausea, vomiting, diarrhea, abdominal pain, and constipation.
  • Timing: Gastrointestinal symptoms frequently occur when starting treatment or increasing dosage.
  • Digestive: Nausea, diarrhea, vomiting, constipation, abdominal discomfort, and indigestion.
  • Other Effects: Decreased appetite and possible injection-site reactions.
  • Timing: Gastrointestinal symptoms frequently occur during dose escalation.

Information Accuracy Disclaimer: Pricing, insurance coverage, medication availability, and other details may change over time. The information presented in this comparison reflects available information as of November 6, 2026. For the most current details, consult the medication manufacturers, your insurance provider, or a qualified healthcare professional.

Important: Both medications carry a boxed warning concerning thyroid C-cell tumors observed in rodents; whether they cause these tumors in humans is unknown. Neither should be used by patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Treatment selection requires an individualized medical assessment.

Weight-loss evidence: In the SURPASS-2 clinical trial, tirzepatide (Mounjaro) produced greater average weight loss and HbA1c reductions than semaglutide (Ozempic) 1 mg after 40 weeks in adults with type 2 diabetes inadequately controlled with metformin.

The study compared Mounjaro 5 mg, 10 mg, and 15 mg against semaglutide 1 mg. These findings support greater average effectiveness at the studied doses but do not establish superiority over every available Ozempic dose or formulation.

Sources:

Medical Disclaimer: This article is intended for informational and educational purposes only and provides a general comparison of Ozempic and Mounjaro. It is not a substitute for professional medical advice, diagnosis, or treatment.

The safety, effectiveness, and suitability of either medication depend on individual medical history, health conditions, and treatment goals. For a comprehensive evaluation and personalized treatment recommendations, consult a qualified healthcare provider before starting, changing, or discontinuing either medication.

Related Ozempic Content

Related Mounjaro Content